A phase 2a randomized vehicle-controlled multi-center study of the safety and efficacy of delgocitinib in subjects with moderate-to-severe alopecia areata.

Alopecia areata/AA is an autoimmune cause of nonscarring hair loss. The pathogenesis of AA involves many immune axes, including Th1/Th2 pathways. Delgocitinib is a pan-Janus kinase/JAK inhibitor that broadly blocks pro-inflammatory cytokines and has been effective in other inflammatory skin conditions.

Progression of undiagnosed cutaneous lymphoma after anti-tumor necrosis factor-alpha therapy.

Background: Cutaneous lymphoma diagnosed after anti-tumor necrosis factor-α therapy (anti-TNF-α) has been reported in the literature, yet a clear link between both events remains elusive.

Objective: To review our experience with cutaneous lymphoma diagnosed during or after the use of anti-TNF-α therapies.

Methods: This is a multicenter retrospective study and a literature review.